Brief: Salubris Pharma Ditches Plan To Obtain Right In Viracta's Nanatinostat In China

Viracta Therapeutics

23/08/2021 13:41

Aug 23 (Reuters) - Shenzhen Salubris Pharmaceuticals Co Ltd
 002294.SZ :
    * SAYS IT TERMINATES PREVIOUS AGREEMENT TO OBTAIN EXCLUSIVE
RIGHT
OF VIRACTA'S NANATINOSTAT IN MAINLAND CHINA

Source text in Chinese: https://bit.ly/388lfsS
Further company coverage:  002294.SZ 

 (Reporting by Hong Kong newsroom)
 ((hongkong.newsroom@thomsonreuters.com; （8610）6627-1277;
Reuters Messaging: roxanne.liu@thomsonreuters.com))